English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

corneas. Invest Ophthalmol Vis Sci. 2000;41: 2514-2522. 3. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies: Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101: 1536-1547. 4. Rosenfeld PJ,MoshfeghiAA,PuliafitoCA.Optical coherence tomography findings after an intravitreal injectionofbevacizumab(Avastin) forneovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335. 5. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in woundand inflammationrelated corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22. 6. Ren M, Manzano RPA, Peyman GA, Khan P, Carvounis P, Kivilcim M. Inhibition of experimental angiogenesis of cornea by bevacizumab [poster 1638/B365]. Presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 1, 2006; Fort Lauderdale, Fla.

Vitreous Band Formation and the Sustained-Release, Intravitreal Fluocinolone (Retisert) Implant